Obstructive Hypertrophic Cardiomyopathy (oHCM) Clinical Trials
2 recruiting trials for Obstructive Hypertrophic Cardiomyopathy (oHCM). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Obstructive Hypertrophic Cardiomyopathy (oHCM) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by China National Center for Cardiovascular Diseases (1), Bristol-Myers Squibb (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Ademetionine 1,4-Butanedisulfonate (drug, 1 trial), followed by Placebo, Mavacamten.
Track Obstructive Hypertrophic Cardiomyopathy (oHCM) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive...
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Obstructive Hypertrophic Cardiomyopathy (oHCM), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Obstructive Hypertrophic Cardiomyopathy (oHCM), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Obstructive Hypertrophic Cardiomyopathy (oHCM), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.